Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IPH 6401

Drug Profile

IPH 6401

Alternative Names: IPH-64; IPH-6401; SAR-445514; SAR’514

Latest Information Update: 16 Jun 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Innate Pharma
  • Developer Innate Pharma; Sanofi
  • Class Antineoplastics; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Amyloid light-chain amyloidosis; Multiple myeloma
  • Preclinical Cancer

Most Recent Events

  • 15 May 2023 Phase-I/II clinical trials in Amyloid light-chain amyloidosis (Second-line therapy or greater, Monotherapy) in Australia (SC) (NCT05839626) (EudraCT2022-502057-33-00)
  • 15 May 2023 Phase-I/II clinical trials in Multiple myeloma (Monotherapy, Second-line therapy or greater) in France (Parenteral) (NCT05839626) (EudraCT2022-502057-33-00)
  • 03 May 2023 Sanofi plans a phase I/II trial for Multiple myeloma (Monotherapy, Refractory metastatic disease, Second-line therapy or greater) (SC) (NCT05839626)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top